Drug intelligence / Profile preview

SBC115

Development stage: Preclinical
Lead developer: SapiensBio
Modality: Small Molecules

Overview

SBC115 is a preclinical-stage small molecule inhibitor of the Actin-related protein 2/3 complex subunit 2 (ARPC2), developed by SapiensBio. Discovered using the company's AI-powered SAPIENTIA platform, SBC115 is an indication expansion of the SBC101 program, targeting a broad range of fibrotic conditions including liver, kidney, cardiac, pancreatic, and skin fibrosis. By inhibiting ARPC2, the drug aims to modulate actin cytoskeleton dynamics to prevent the pathological activation of fibroblasts into myofibroblasts, a key driver of tissue scarring. Efficacy has been demonstrated in human hepatic stellate cell models, and the program is currently undergoing in vivo evaluation to support its development across multiple organ-specific fibrotic diseases.

Targets

ARPC2 (Actin-related protein 2/3 complex subunit 2)

Beyond the preview

Go deeper on SBC115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBC115.

Explore the full profile